Long-term outcomes of induction chemotherapy followed by chemoradiotherapy using volumetric-modulated arc therapy as an organ preservation approach in patients with stage IVA-B oropharyngeal or hypopharyngeal cancers.
Adult
Aged
Aged, 80 and over
Chemoradiotherapy
/ methods
Female
Humans
Hypopharyngeal Neoplasms
/ drug therapy
Induction Chemotherapy
Kaplan-Meier Estimate
Male
Middle Aged
Multivariate Analysis
Organ Preservation
Oropharyngeal Neoplasms
/ drug therapy
Predictive Value of Tests
Progression-Free Survival
Radiotherapy, Intensity-Modulated
/ methods
Retrospective Studies
Treatment Outcome
Xerostomia
chemoradiotherapy
hypopharyngeal cancer
induction chemotherapy
oropharyngeal cancer
volumetric-modulated arc therapy
Journal
Journal of radiation research
ISSN: 1349-9157
Titre abrégé: J Radiat Res
Pays: England
ID NLM: 0376611
Informations de publication
Date de publication:
06 Jul 2020
06 Jul 2020
Historique:
received:
07
04
2020
revised:
27
04
2020
accepted:
11
05
2020
pubmed:
18
6
2020
medline:
9
7
2021
entrez:
18
6
2020
Statut:
ppublish
Résumé
The present study aimed to analyze treatment outcomes after induction chemotherapy followed by chemoradiotherapy (CRT) using volumetric-modulated arc therapy (VMAT) in patients with stage IVA-B oropharyngeal cancer (OPC) or hypopharyngeal cancer (HPC), with long-term observation, including examination of larynx preservation. A total of 60 patients with stage IVA-B OPC or HPC, who underwent induction TPF chemotherapy (a combination regimen consisting of docetaxel, cisplatin, and 5-fluorouracil) followed by CRT using VMAT were analyzed. Overall survival (OS), progression-free survival (PFS), laryngoesophageal dysfunction-free survival (LEDFS), and locoregional control (LRC) were calculated and compared. Univariate and multivariate analyses were performed to determine statistical differences in OS and LEDFS. The median follow-up period at the time of evaluation was 61 months. Twenty-six (43%) patients had OPC and 34 (57%) had HPC. The 5-year OS, PFS, LEDFS, and LRC rates were 57%, 52%, 52%, and 68%, respectively. Response to TPF therapy was the only significant predictive factor of OS and LEDFS in multivariate analyses. Regarding long-term toxicities, grade ≥ 2 late toxicities accounted for 15%. No patients experienced grade ≥ 3 xerostomia, and 5% of all patients developed grade 3 dysphagia. With long-term observation, the OS, PFS, and LEDFS rates were relatively good, and the incidence of late toxicities was low. TPF followed by CRT using VMAT was feasible and more effective in those who responded to induction chemotherapy.
Identifiants
pubmed: 32548612
pii: 5858247
doi: 10.1093/jrr/rraa033
pmc: PMC7336564
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
554-562Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of The Japanese Radiation Research Society and Japanese Society for Radiation Oncology.
Références
Jpn J Clin Oncol. 2017 Nov 1;47(11):1031-1037
pubmed: 28973501
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Cancer. 2011 Oct 1;117(19):4447-51
pubmed: 21437891
J Natl Cancer Inst. 2015 Dec 16;108(4):
pubmed: 26681800
J Clin Oncol. 2013 Mar 1;31(7):845-52
pubmed: 23182993
Jpn J Clin Oncol. 2016 Apr;46(4):344-9
pubmed: 26826721
Laryngoscope. 1995 Apr;105(4 Pt 1):397-406
pubmed: 7715386
Cancer Med. 2020 Mar;9(5):1671-1682
pubmed: 31943834
Int J Clin Oncol. 2019 Jul;24(7):789-797
pubmed: 30796560
Front Oncol. 2019 Jan 22;9:6
pubmed: 30723701
Head Neck Surg. 1987 Sep-Oct;10(1):4-13
pubmed: 3449480
Lancet Oncol. 2011 Feb;12(2):153-9
pubmed: 21233014
Anticancer Res. 2016 Dec;36(12):6625-6630
pubmed: 27919993
Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):410-5
pubmed: 18635320
Int J Radiat Oncol Biol Phys. 2009 Apr 1;73(5):1293-303
pubmed: 19306746
J Natl Cancer Inst. 2009 Feb 4;101(3):142-52
pubmed: 19176454
Front Oncol. 2019 Jul 10;9:625
pubmed: 31355142
Int J Clin Oncol. 2015 Jun;20(3):431-7
pubmed: 24993675
Cancer. 2008 Nov 15;113(10):2797-806
pubmed: 18839393
Laryngoscope. 2017 Aug;127(8):1791-1796
pubmed: 27888508